Product image of Mifomet (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Mifomet

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Mifomet (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredients in Mifomet, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They treat type 2 diabetes mellitus in adult patients.
GNH India supplies Mifomet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bausch Health Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mifomet, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: improves glycemic control when combined with diet and exercise.
  • Inadequate control on metformin alone: adds a complementary mechanism to lower blood glucose.
  • Inadequate control on sitagliptin alone: provides additional glucose‑lowering effect through a different pathway.

How It Works

  • Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased incretin levels that stimulate glucose‑dependent insulin secretion and suppress glucagon release, together achieving better glycemic control in type 2 diabetes.

Side Effects

Mifomet may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: frequent loose stools, especially at treatment initiation.
  • Abdominal discomfort: cramping or pain in the stomach area.
  • Headache: transient mild headache.
  • Hypoglycemia (when used with sulfonylureas or insulin): low blood sugar episodes.
  • Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic condition.
  • Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or liver injury.
  • Renal impairment: worsening kidney function, especially in dehydration.
  • Severe hypoglycemia: prolonged low blood glucose requiring medical intervention.

Precautions & Warnings

Before prescribing Mifomet, clinicians should evaluate patient-specific risk factors and monitor for adverse events.

  • Renal function assessment: ensure adequate kidney function before initiation.
  • Hepatic function monitoring: avoid in patients with significant liver disease.
  • Contraindicated in severe renal impairment: do not use when eGFR is below the recommended threshold.
  • Monitor for signs of lactic acidosis: educate patients on symptoms.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.
  • Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Mifomet can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Alcohol: increases risk of lactic acidosis when combined with metformin.
  • Iodinated contrast agents: may precipitate acute renal failure, requiring temporary discontinuation.
  • Cimetidine: can raise metformin plasma concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas: heightened risk of hypoglycemia; dose adjustments may be needed.
  • Rifampin: may reduce sitagliptin exposure, decreasing efficacy.
  • Diuretics: can affect renal clearance of metformin, requiring monitoring.

Frequently Asked Questions

Mifomet is a prescription oral medication that combines metformin hydrochloride and sitagliptin. It is indicated for the treatment of type 2 diabetes mellitus in adults, helping to lower blood glucose levels when diet, exercise, and lifestyle changes alone are insufficient.

Metformin lowers glucose production by the liver and improves insulin sensitivity in peripheral tissues. Sitagliptin blocks the enzyme DPP‑4, which increases levels of incretin hormones that stimulate insulin release and suppress glucagon after meals. Together they provide complementary mechanisms to improve glycemic control.

The dosage of Mifomet is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the dose and administration schedule provided by their prescriber.

The safety of Mifomet in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Mifomet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mifomet combines two distinct mechanisms—biguanide (metformin) and DPP‑4 inhibition (sitagliptin)—offering broader glucose control than either agent alone. Compared with sulfonylureas, it carries a lower risk of hypoglycemia, and unlike insulin, it is administered orally.

Mifomet tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Mifomet is taken orally, usually once daily with a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and pancreatitis, which can occur with sitagliptin. Patients should seek immediate medical attention for symptoms such as severe abdominal pain, rapid breathing, or unexplained fatigue.

Mifomet is contraindicated in patients with severe renal impairment, significant hepatic disease, a history of lactic acidosis, or known hypersensitivity to metformin, sitagliptin, or any excipients. It should also be avoided in individuals with uncontrolled heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT